TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office November 20, 1992